戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 gle-agent chemotherapy using methotrexate or dactinomycin.
2  cisplatin, bleomycin, cyclophosphamide, and dactinomycin.
3 e, etoposide catechol, etoposide quinone, or dactinomycin.
4 apy started at week 9 along with vincristine/dactinomycin.
5 e-dose (pulse-intensive [PI]) treatment with dactinomycin.
6 e-dose (pulse-intensive [PI]) treatment with dactinomycin.
7 ance to Vinca alkaloids and no resistance to dactinomycin.
8 g/m(2), and either doxorubicin 75 mg/m(2) or dactinomycin 1.25 mg/m(2).
9 ernating courses of vincristine 1.5 mg/m(2), dactinomycin 1.5 mg/m(2), and cyclophosphamide 2.2 g/m(2
10 , both p<0.0001); for liver transplantation, dactinomycin (3.8, 1.3-11.3) and methotrexate (3.3, 1.0-
11 alternating with vincristine (V; 1.5/mg/m2), dactinomycin (A; 1.5 mg/m2), and cyclophosphamide (C; 2.
12 romoter, and pretreatment of HT29 cells with dactinomycin abrogated the induction of VEGF mRNA by IGF
13 quently receive etoposide, methotrexate, and dactinomycin alternating weekly with cyclophosphamide an
14 ne, cyclophosphamide, doxorubicin (VDC), and dactinomycin alternating with ifosfamide and etoposide (
15 ated with use of etoposide, methotrexate and dactinomycin, alternating with cyclophosphamide and vinc
16  alternated courses of VTC with vincristine, dactinomycin and cyclophosphamide (VAC) during weeks 6 t
17  (5 days) or single-dose (PI) treatment with dactinomycin and divided-dose (ST) courses (3 days) or s
18  disease received regimen DD4A (vincristine, dactinomycin and doxorubicin) but no radiation therapy.
19 cyclophosphamide, ifosfamide, etoposide, and dactinomycin and identified prognostic factors now used
20 ite on P-glycoprotein for substrates such as dactinomycin and vinblastine and for inhibitors such as
21  time of closure were recalled, treated with dactinomycin and vincristine (regimen EE4A), and censore
22 sfamide and etoposide (IE) with vincristine, dactinomycin, and cyclophosphamide (VAC) or vincristine,
23 -free survival (FFS) rates with vincristine, dactinomycin, and cyclophosphamide (VAC; total cumulativ
24 h vincristine and dactinomycin (vincristine, dactinomycin, and cyclophosphamide [VAC] v vincristine,
25           Patients who received vincristine, dactinomycin, and cyclophosphamide in addition to cispla
26 RMS) treated with standard VAC (vincristine, dactinomycin, and cyclophosphamide) chemotherapy to that
27 /IV disease received regimen M (vincristine, dactinomycin, and doxorubicin alternating with cyclophos
28 s tumor (FHWT) is Regimen DD4A (vincristine, dactinomycin, and doxorubicin) and radiation therapy.
29  3-drug induction chemotherapy (vincristine, dactinomycin, and doxorubicin) for 6 or 12 weeks based o
30 herapy consisting of 6 weeks of vincristine, dactinomycin, and epirubicin or doxorubicin.
31 poside (VIDE) and one course of vincristine, dactinomycin, and ifosfamide (VAI) before either BuMel o
32 n, and cyclophosphamide [VAC] v vincristine, dactinomycin, and ifosfamide [VAI]) after an intensive i
33 HD MTX) and bleomycin, cyclophosphamide, and dactinomycin (BCD).
34 e course of bleomycin, cyclophosphamide, and dactinomycin (BCD).
35 apy when using vincristine, doxorubicin, and dactinomycin, but their long-term survival is unchanged
36 atient previously administered etoposide and dactinomycin by molecular and biochemical approaches to
37 enders yeast sensitive to anthracyclines and dactinomycin, clinically relevant Pgp substrates.
38 cin (DOX) to the combination of vincristine, dactinomycin, cyclophosphamide (VAC), and XRT did not si
39 djuvant chemotherapy comprising vincristine, dactinomycin, cyclophosphamide, and doxorubicin or were
40 (etoposide, high-dose methotrexate [1 g/m2], dactinomycin, cyclophosphamide, and vincristine sulfate)
41 isted of ifosfamide, etoposide, doxorubicin, dactinomycin, cyclophosphomide, and vincristine, and a s
42 ly elevated risks were seen for doxorubicin, dactinomycin, dacarbazine, and carmustine.
43 d tomography after two cycles of vincristine/dactinomycin/doxorubicin (Regimen DD-4A) chemotherapy, i
44       Etoposide and its metabolites, but not dactinomycin, enhanced cleavage at these sites.
45 ts treated with etoposide, methotrexate, and dactinomycin followed by cyclophosphamide and vincristin
46 stage I AH were treated with vincristine and dactinomycin for 18 weeks.
47 ate nephrectomy, and therefore, the risks of dactinomycin hepatopathy can be avoided.
48 cristine, doxorubicin, cyclophosphamide, and dactinomycin improved outcomes.
49  receive either ifosfamide, vincristine, and dactinomycin (IVA) or a six-drug combination (IVA plus c
50    Etoposide and/or its metabolites, but not dactinomycin, likely were the relevant exposures in this
51 orubicin, vincristine, cyclophosphamide, and dactinomycin or experimental therapy with these four dru
52 ted patients, shorter courses of vincristine/dactinomycin or vincristine alone show equivalent result
53 orubicin, vincristine, cyclophosphamide, and dactinomycin (regimen A) or these 4 drugs alternating wi
54 t expression of the murine mdr3 gene confers dactinomycin resistance in both the erg6 mutant yeast st
55 analog valspodar (PSC 833), vinblastine, and dactinomycin stimulated ATPase activity in Dx5 but not i
56 s were randomized to receive vincristine and dactinomycin (VA) and cyclophosphamide (VAC, n = 235), o
57 , 26.4 g/m(2)) compared with vincristine and dactinomycin (VA) for patients with subset-one low-risk
58 orubicin, vincristine, cyclophosphamide, and dactinomycin, (VACA) or with these four drugs alternatin
59 osfamide in combination with vincristine and dactinomycin (vincristine, dactinomycin, and cyclophosph
60 T-cyclophosphamide, ifosfamide, doxorubicin, dactinomycin, vincristine, etoposide - at standard dosag
61 postoperatively bleomycin, cyclophosphamide, dactinomycin, vincristine, methotrexate, doxorubicin, an
62                       With aclacinomycin and dactinomycin, we initially identified two FDA-approved d
63 ent (nine cycles of ifosfamide, vincristine, dactinomycin with or without doxorubicin, and surgery or